- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07862569
DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg
A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Doravirine/Islatravir (100 mg/0.25 mg) in Pediatric Participants With HIV-1 Infection Who Are Virologically Suppressed or Treatment-Naïve, Are Less Than 18 Years of Age, and Weigh Greater Than or Equal to 35 kg
This is a phase 2 study of the pharmacokinetics, safety, and efficacy of oral doravirine/islatravir (100 mg/0.25 mg) [MK-8591A] in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection who are virologically suppressed or treatment-naive.
The Base Study will last from Day 1 to Week 96. At Week 96, participants will be given the option to participate in an optional Study Extension and receive DOR/ISL until Week 240 or until it becomes commercially accessible, whichever is first.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Toll Free Number
- Telefoonnummer: 1-888-577-8839
- E-mail: Trialsites@merck.com
Studie Locaties
-
-
Florida
-
Tampa, Florida, Verenigde Staten, 33612
- University of South Florida ( Site 1505)
-
Contact:
- Study Coordinator
- Telefoonnummer: 813-821-8039
-
-
New York
-
The Bronx, New York, Verenigde Staten, 10467
- The Children's Hospital at Montefiore ( Site 1507)
-
Contact:
- Study Coordinator
- Telefoonnummer: 718-741-2497
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Pediatric participant with HIV-1 <18 years of age
- Body weight ≥35 kg
- Is TN (HIV-1 positive with plasma HIV-1 RNA ≥500 copies/mL) or VS (HIV-1 positive at screening with plasma HIV-1 RNA <50 copies/mL AND has received stable, continuous 2- or 3-drug antiretroviral therapy (ART) for ≥3 months prior to providing informed consent)
Exclusion Criteria:
- HIV-2 infection
- Hypsensitivity/contraindication to any components of study medication or as determined by the investigator
- Has an active diagnosis of hepatitis due to any cause
- history of malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma
- Has a history or current evidence of any condition (including active tuberculosis infection, COVID-19, or other infections), therapy, laboratory abnormality, or other circumstance (including drug or alcohol use or dependence) that might, in the opinion of the investigator, confound the results of the study
- Is taking or is anticipated to require systemic immunosuppressive therapy, immune modulators, or any prohibited therapies
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: DOR/ISL
Participants receive DOR/ISL 100 mg/0.25 mg once daily (qd) for 96 weeks. Participants will have the option to participate in the Study Extension and receive DOR/ISL until Week 240 or it becomes commercially available, whichever is first. |
DOR/ISL 100 mg/0.25 mg tablet taken by mouth qd
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Area under the plasma conentration-time curve from dosing to 24 hours postdose (AUC0-24) of ISL
Tijdsspanne: At designated timepoints on Day 28
|
The plasma AUC0-24 will be assessed. |
At designated timepoints on Day 28
|
|
Maximum plasma concentration (Cmax) of ISL
Tijdsspanne: At designated timepoints on Day 28
|
The plasma Cmax will be assessed. |
At designated timepoints on Day 28
|
|
Time to maximum plasma concentration (Tmax) of ISL
Tijdsspanne: At designated timepoints on Day 28
|
The plasma Tmax will be assessed. |
At designated timepoints on Day 28
|
|
Apparent plasma terminal half-life (t½) of ISL
Tijdsspanne: At designated timepoints on Day 28
|
The plasma t½ will be assessed. |
At designated timepoints on Day 28
|
|
Apparent clearance (CL/F) of ISL
Tijdsspanne: At designated timepoints on Day 28
|
The CL/F will be assessed. |
At designated timepoints on Day 28
|
|
Volume of distribution (Vz/F) of ISL
Tijdsspanne: At designated timepoints on Day 28
|
The Vz/F will be assessed. |
At designated timepoints on Day 28
|
|
Percentage of participants with ≥1 adverse event (AE) through Week 24
Tijdsspanne: Up to ~24 weeks
|
The percentage of participants with AE(s) will be assessed. |
Up to ~24 weeks
|
|
Percentage of participants discontinuing from study therapy due to AE(s) through Week 24
Tijdsspanne: Up to ~24 weeks
|
The percentage of participants discontinuing from therapy due to AE(s) will be assessed. |
Up to ~24 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of participants with ≥1 AE through Week 96
Tijdsspanne: Up to 96 weeks
|
The percentage of participants with AE(s) will be assessed. |
Up to 96 weeks
|
|
Percentage of participants discontinuing from study therapy due to AE(s) through Week 96
Tijdsspanne: Up to 96 weeks
|
The percentage of participants with AE(s) will be assessed. |
Up to 96 weeks
|
|
Percentage of virologically-suppressed (VS) participants with Human Immunodeficiency Virus Type 1 (HIV-1) ribonucleic acid (RNA) ≥50 copies/mL
Tijdsspanne: Weeks 24, 48, and 96
|
The percentage of VS participants with HIV-1 RNA ≥50 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Percentage of VS participants with HIV-1 RNA <50 copies/mL
Tijdsspanne: Weeks 24, 48, and 96
|
The percentage of VS participants with HIV-1 RNA <50 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Percentage of VS participants with HIV-1 RNA <200 copies/mL
Tijdsspanne: Weeks 24, 48, and 96
|
The percentage of VS participants with HIV-1 RNA <200 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Percentage of treatment-naive (TN) participants with HIV-1 RNA <50 copies/mL
Tijdsspanne: Weeks 24, 48, and 96
|
The percentage of TN participants with HIV-1 RNA <50 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Percentage of TN participants with HIV-1 RNA <200 copies/mL
Tijdsspanne: Weeks 24, 48, and 96
|
The percentage of TN participants with HIV-1 RNA <200 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Change from baseline in CD4+ T-cell counts in VS and TN participants
Tijdsspanne: Weeks 24, 48, and 96
|
The change from baseline in CD4+ T-cell counts will be assessed in VS and TN participants. |
Weeks 24, 48, and 96
|
|
Percentage of participants with viral drug resistance to DOR or ISL
Tijdsspanne: Weeks 24, 48, 96, and 144
|
The percentage of participants with viral resistance-associated substitutions will be assessed during Weeks 24, 48, 96, and 144. |
Weeks 24, 48, 96, and 144
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Door bloed overgedragen infecties
- Urogenitale ziekten
- Genitale ziekten
- Ziekten van het immuunsysteem
- Infecties
- RNA-virusinfecties
- Virusziekten
- Overdraagbare ziekten
- Seksueel overdraagbare aandoeningen, viraal
- Seksueel overdraagbare aandoeningen
- Lentivirus-infecties
- Retroviridae-infecties
- Immunologische deficiëntie syndromen
- HIV-infecties
Andere studie-ID-nummers
- 8591A-063
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .